AU2001257521A1 - Prostaglandin compounds for treating congestive heart failure - Google Patents
Prostaglandin compounds for treating congestive heart failureInfo
- Publication number
- AU2001257521A1 AU2001257521A1 AU2001257521A AU5752101A AU2001257521A1 AU 2001257521 A1 AU2001257521 A1 AU 2001257521A1 AU 2001257521 A AU2001257521 A AU 2001257521A AU 5752101 A AU5752101 A AU 5752101A AU 2001257521 A1 AU2001257521 A1 AU 2001257521A1
- Authority
- AU
- Australia
- Prior art keywords
- heart failure
- congestive heart
- treating congestive
- prostaglandin compounds
- prostaglandin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 206010007559 Cardiac failure congestive Diseases 0.000 title 1
- 206010019280 Heart failures Diseases 0.000 title 1
- -1 Prostaglandin compounds Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
- A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Otolaryngology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09587458 | 2000-06-05 | ||
US09/587,458 US6242482B1 (en) | 2000-06-05 | 2000-06-05 | Prostaglandin compounds and derivatives thereof, compositions containing the same and method of using the same for the treatment of congestive heart failure |
PCT/US2001/014338 WO2001093862A1 (en) | 2000-06-05 | 2001-05-03 | Prostaglandin compounds for treating congestive heart failure |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001257521A1 true AU2001257521A1 (en) | 2001-12-17 |
Family
ID=24349885
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001257521A Abandoned AU2001257521A1 (en) | 2000-06-05 | 2001-05-03 | Prostaglandin compounds for treating congestive heart failure |
Country Status (8)
Country | Link |
---|---|
US (1) | US6242482B1 (en) |
EP (1) | EP1299096A1 (en) |
JP (1) | JP2003535132A (en) |
KR (1) | KR20030038547A (en) |
CN (1) | CN1433307A (en) |
AU (1) | AU2001257521A1 (en) |
CA (1) | CA2408542A1 (en) |
WO (1) | WO2001093862A1 (en) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6803386B2 (en) | 2002-01-16 | 2004-10-12 | United Therapeutics Corporation | Prostacyclin derivative containing compositions and methods of using the same for the treatment of cancer |
DE10209821A1 (en) | 2002-03-06 | 2003-09-25 | Biotechnologie Ges Mittelhesse | Coupling of proteins to a modified polysaccharide |
DE10209822A1 (en) * | 2002-03-06 | 2003-09-25 | Biotechnologie Ges Mittelhesse | Coupling of low molecular weight substances to a modified polysaccharide |
ES2670872T3 (en) | 2003-05-22 | 2018-06-01 | United Therapeutics Corporation | Polymorph of a treprostinil diethanolamine salt |
WO2005014655A2 (en) | 2003-08-08 | 2005-02-17 | Fresenius Kabi Deutschland Gmbh | Conjugates of hydroxyalkyl starch and a protein |
CA2574958A1 (en) * | 2004-07-26 | 2006-02-09 | Cotherix, Inc. | Treatment of pulmonary hypertension by inhaled iloprost with a microparticle formulation |
US20070042016A1 (en) * | 2005-06-23 | 2007-02-22 | Medtronic Vascular, Inc. | Methods and Systems for Treating Injured Cardiac Tissue |
US20080200449A1 (en) | 2006-05-15 | 2008-08-21 | United Therapeutics Corporation | Treprostinil administration using a metered dose inhaler |
KR101950526B1 (en) * | 2011-01-13 | 2019-02-20 | 에스씨아이팜 에스에이알엘 | Method for enhancing engraftment of haematopoetic stem cells |
AU2012296953B2 (en) * | 2011-08-12 | 2016-10-20 | Ascendis Pharma A/S | Sustained release composition of prostacyclin |
EP2674413B1 (en) * | 2012-06-15 | 2017-06-07 | SciPharm SàRL | Process for the preparation of treprostinil and derivatives thereof |
AU2013353985B2 (en) * | 2012-12-07 | 2017-07-13 | Ascendis Pharma A/S | Carrier-linked prostanoid prodrugs |
US9505737B2 (en) | 2013-01-11 | 2016-11-29 | Corsair Pharma, Inc. | Treprostinil derivative compounds and methods of using same |
EP4137127A1 (en) | 2013-01-11 | 2023-02-22 | Corsair Pharma, Inc. | Prodrugs of treprostinil |
WO2014179295A1 (en) | 2013-04-30 | 2014-11-06 | United Therapeutics Corporation | Controlled release pharmaceutical formulations |
BR112016009207B1 (en) | 2013-10-25 | 2022-11-22 | Insmed Incorporated | PROSTACYCLIN COMPOUNDS |
JP6561109B2 (en) * | 2014-07-16 | 2019-08-14 | コルセア ファーマ インコーポレイテッド | Treprostinil derivative compound and method of using the same |
CA2967385C (en) | 2014-11-18 | 2023-05-16 | Insmed Incorporated | Methods of manufacturing treprostinil and treprostinil derivative prodrugs |
US9643911B2 (en) | 2015-06-17 | 2017-05-09 | Corsair Pharma, Inc. | Treprostinil derivatives and compositions and uses thereof |
US9394227B1 (en) | 2015-06-17 | 2016-07-19 | Corsair Pharma, Inc. | Treprostinil derivatives and compositions and uses thereof |
US10883084B2 (en) | 2018-10-05 | 2021-01-05 | Xenotherapeutics, Inc. | Personalized cells, tissues, and organs for transplantation from a humanized, bespoke, designated-pathogen free, (non-human) donor and methods and products relating to same |
IL281867B1 (en) | 2018-10-05 | 2024-03-01 | Xenotherapeutics Inc | Xenotransplantation products and methods |
MX2021013329A (en) | 2019-04-29 | 2022-03-17 | Insmed Inc | Dry powder compositions of treprostinil prodrugs and methods of use thereof. |
JP2020011957A (en) * | 2019-07-22 | 2020-01-23 | コルセア ファーマ インコーポレイテッド | Treprostinil derivative compound and method of using the same |
EP4135707A1 (en) | 2020-04-17 | 2023-02-22 | United Therapeutics Corporation | Treprostinil for use in the treatment of intersitial lung disease |
JP7138685B2 (en) * | 2020-10-26 | 2022-09-16 | コルセア ファーマ インコーポレイテッド | Treprostinil derivative compounds and methods of use thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
EP1164846A1 (en) | 1999-03-31 | 2002-01-02 | United Therapeutics Corporation | Prostaglandin compounds, compositions and methods of treating peripheral vascular disease and pulmonary hypertension |
-
2000
- 2000-06-05 US US09/587,458 patent/US6242482B1/en not_active Expired - Lifetime
-
2001
- 2001-05-03 CN CN01810746A patent/CN1433307A/en active Pending
- 2001-05-03 AU AU2001257521A patent/AU2001257521A1/en not_active Abandoned
- 2001-05-03 WO PCT/US2001/014338 patent/WO2001093862A1/en not_active Application Discontinuation
- 2001-05-03 CA CA002408542A patent/CA2408542A1/en not_active Abandoned
- 2001-05-03 JP JP2002501435A patent/JP2003535132A/en not_active Withdrawn
- 2001-05-03 EP EP01931045A patent/EP1299096A1/en not_active Withdrawn
- 2001-05-03 KR KR1020027015914A patent/KR20030038547A/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CN1433307A (en) | 2003-07-30 |
CA2408542A1 (en) | 2001-12-13 |
WO2001093862A1 (en) | 2001-12-13 |
JP2003535132A (en) | 2003-11-25 |
US6242482B1 (en) | 2001-06-05 |
KR20030038547A (en) | 2003-05-16 |
EP1299096A1 (en) | 2003-04-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001257521A1 (en) | Prostaglandin compounds for treating congestive heart failure | |
EP1180040A4 (en) | Methods for treating congestive heart failure | |
AU2879299A (en) | Controlling congestive heart failure | |
AU2002221239A1 (en) | Therapeutic benzimidazole compounds | |
AU2003214214A1 (en) | Method for treating congestive heart failure | |
AU2002225730A1 (en) | Compounds | |
AUPQ253199A0 (en) | Non-prostanoid prostaglandin I2-agonist | |
AU5690900A (en) | Process for oxidising aromatic compounds | |
AUPQ661800A0 (en) | Insulin-potentiating compounds | |
AU2001239765A1 (en) | Novel compounds | |
AU2001246998A1 (en) | Novel compounds | |
MXPA03008205A (en) | Process for the preparation of imidazole compounds. | |
AU6032100A (en) | New compounds | |
AU2001253362A1 (en) | Novel compounds | |
AU2001256964A1 (en) | Novel compounds | |
AU5935600A (en) | Phosphoramide compounds | |
AU2002225724A1 (en) | Motilide compounds | |
AU2002218171A1 (en) | Method for producing aryl compounds | |
AU1950899A (en) | Compounds for increased bioavailability | |
AU2002217285A1 (en) | Compounds | |
AU2001230689A1 (en) | Novel compounds | |
AU2002214954A1 (en) | Process for the preparation of phenylphenol compounds | |
AU5887400A (en) | Derivative compounds | |
AU6870600A (en) | Process for the preparation of 2,3-dihydroazepine compounds | |
AU3324700A (en) | Imidazole compounds |